The 6 drugs tracked here made $33.3B of AstraZeneca’s 2025 revenue (57%) and lose US exclusivity by 2035. Since 2023, AstraZeneca has closed 3 acquisitions of $1B or more, worth $4.3B in total.
Bars are each drug's 2025 sales as a share of AstraZeneca’s total revenue ($58.7B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Feb 2023 | CinCor PharmaAstraZeneca, February 2023 | $1.3B | Cardiometabolic | Baxdrostat, a drug for hard-to-control high blood pressurePlus a CVR worth up to $0.5B. | Pipeline only |
| Feb 2024 | Gracell BiotechnologiesAstraZeneca, February 2024 | $1.0B | Oncology | GC012F, a CAR-T cell therapy for multiple myeloma and autoimmune diseasePlus a CVR worth up to $0.2B. | Pipeline only |
| Jun 2024 | Fusion PharmaceuticalsFusion 8-K, June 2024 | $2.0B | Oncology | Radioconjugate cancer drugs, led by FPI-2265 for prostate cancerPlus a CVR worth up to $0.4B. | Pipeline only |
| 3 counted | $4.3B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price AstraZeneca announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | $20.2B | $3.0B |
| Cardiometabolic | $8.4B | $1.3B |
| Other | $4.7B | – |
Oncology is where AstraZeneca has the most revenue at risk and where it has spent the most on acquisitions. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what AstraZeneca paid, not the sales it will bring in. None of the companies it bought had an approved product at closing, so any sales from them are years away and may never arrive. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: AZ FY2025. Drug sales and dates are sourced on each drug's page; each deal links to AstraZeneca’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →